×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
APLT – applied therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
APLT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/3
08:54 am
aplt
Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics [Yahoo! Finance]
Neutral
Report
Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics [Yahoo! Finance]
2/3
08:39 am
aplt
Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics
Neutral
Report
Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics
1/29
08:15 am
aplt
Applied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration Extension
Low
Report
Applied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration Extension
1/28
09:07 am
aplt
Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer [Yahoo! Finance]
Low
Report
Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer [Yahoo! Finance]
12/16
11:21 am
aplt
Halper Sadeh LLC Encourages QIPT, FITB, GBIO, APLT Shareholders to Contact the Firm to Discuss Their Rights
Medium
Report
Halper Sadeh LLC Encourages QIPT, FITB, GBIO, APLT Shareholders to Contact the Firm to Discuss Their Rights
12/13
07:49 am
aplt
Applied Therapeutics (NASDAQ:APLT) was downgraded by analysts at Baird R W from a "strong-buy" rating to a "hold" rating.
Medium
Report
Applied Therapeutics (NASDAQ:APLT) was downgraded by analysts at Baird R W from a "strong-buy" rating to a "hold" rating.
12/12
01:05 pm
aplt
Applied Therapeutics (NASDAQ:APLT) was given a new $0.25 price target on by analysts at Robert W. Baird.
Low
Report
Applied Therapeutics (NASDAQ:APLT) was given a new $0.25 price target on by analysts at Robert W. Baird.
12/12
10:09 am
aplt
Applied Therapeutics (NASDAQ:APLT) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating.
Low
Report
Applied Therapeutics (NASDAQ:APLT) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating.
Date
Time
Symbol
Company Name
Action
%Chg
11/13/2025
07:00 am
aplt
applied therapeutics, inc.
BEAT
Report
-52.6%
applied therapeutics, inc.
8/13/2025
05:11 pm
aplt
applied therapeutics, inc.
BEAT
Report
7.3%
applied therapeutics, inc.
5/13/2025
05:00 pm
aplt
applied therapeutics, inc.
BEAT
Report
9.0%
applied therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/3
04:09 pm
aplt
Form POS AM Applied Therapeutics,
Neutral
Report
Form POS AM Applied Therapeutics,
2/3
04:08 pm
aplt
Form POS AM Applied Therapeutics,
Neutral
Report
Form POS AM Applied Therapeutics,
2/3
04:07 pm
aplt
Form S-8 POS Applied Therapeutics,
Neutral
Report
Form S-8 POS Applied Therapeutics,
2/3
04:05 pm
aplt
Form S-8 POS Applied Therapeutics,
Neutral
Report
Form S-8 POS Applied Therapeutics,
2/3
04:04 pm
aplt
Form S-8 POS Applied Therapeutics,
Neutral
Report
Form S-8 POS Applied Therapeutics,
2/3
04:02 pm
aplt
Form S-8 POS Applied Therapeutics,
Neutral
Report
Form S-8 POS Applied Therapeutics,
2/3
09:41 am
aplt
Form 25-NSE Applied Therapeutics, Filed by: Nasdaq Stock Market LLC
Neutral
Report
Form 25-NSE Applied Therapeutics, Filed by: Nasdaq Stock Market LLC
2/3
09:09 am
aplt
Form 8-K Applied Therapeutics, For: Feb 03
Neutral
Report
Form 8-K Applied Therapeutics, For: Feb 03
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/8
Applied Therapeutics Announces Positive Topline Results of Pivotal Phase 2 ACTION-Galactosemia Study of AT-007 in Galactosemia Patients
41.5%
1/9 Applied Therapeutics (NASDAQ: APLT) had its price target raised by analysts at Citigroup Inc from $29.00 to $44.00. They now have a "buy" rating on the stock. 25.7%
5/13 Form 3 Applied Therapeutics For: May 13 Filed by: Funtleyder Leslie D. 16.9%
12/23 Form EFFECT Applied Therapeutics 14.4%
4/3 Form 3 Applied Therapeutics For: Apr 01 Filed by: Mahadevan Chids 9.9%
12/19 Form S-1/A Applied Therapeutics 7.3%
1/29 Form 4 Applied Therapeutics For: Jan 28 Filed by: MARCUS JOEL S 7.1%
3/13 Form 8-K Applied Therapeutics For: Mar 13 7.0%
3/3 Applied Therapeutics Appoints Adam Hansard as Chief Commercial Officer 6.5%
6/10 Applied Therapeutics (NASDAQ: APLT) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 6.5%
1/9 Applied Therapeutics (NASDAQ: APLT) had its price target raised by analysts at Citigroup Inc from $29.00 to $44.00. They now have a "buy" rating on the stock. 25.7%
5/13 Form 3 Applied Therapeutics For: May 13 Filed by: Funtleyder Leslie D. 16.9%
12/23 Form EFFECT Applied Therapeutics 14.4%
4/3 Form 3 Applied Therapeutics For: Apr 01 Filed by: Mahadevan Chids 9.9%
12/19 Form S-1/A Applied Therapeutics 7.3%
1/29 Form 4 Applied Therapeutics For: Jan 28 Filed by: MARCUS JOEL S 7.1%
3/13 Form 8-K Applied Therapeutics For: Mar 13 7.0%
3/3 Applied Therapeutics Appoints Adam Hansard as Chief Commercial Officer 6.5%
6/10 Applied Therapeutics (NASDAQ: APLT) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 6.5%
TOP News Decliners
3/16
Form POS AM Applied Therapeutics
-29.8%
3/10 Applied Therapeutics (NASDAQ: APLT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -13.2%
3/11 Form 4 Applied Therapeutics For: Mar 09 Filed by: Hansard Adam -11.9%
4/21 Applied Therapeutics Announces Full Data and Scientific Presentations from the Pivotal Phase 2 ACTION-Galactosemia Trial -11.8%
6/21 Applied Therapeutics Reports First Quarter 2019 Financial Results -11.0%
12/5 Applied Therapeutics Announces Presentations Outlining the Design and Rationale for the ARISE-HF Pivotal Study of AT-001 for Treatment of Diabetic Cardiomyopathy at the 16th Annual Global Cardiovascular Clinical Trialist’s Forum (CVCT) -10.4%
3/31 Form 4 Applied Therapeutics For: Mar 27 Filed by: Alexandria Venture Investments, LLC -10.0%
3/5 Applied Therapeutics (APLT) Investor Presentation - Slideshow [Seeking Alpha] -9.3%
6/5 Form 4 Applied Therapeutics For: Jun 03 Filed by: Funtleyder Leslie D. -9.0%
8/8 Applied Therapeutics Reports AT-007 SAD Data from Healthy Volunteer Portion of Phase 1/2 ACTION-Galactosemia Study -8.1%
3/10 Applied Therapeutics (NASDAQ: APLT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -13.2%
3/11 Form 4 Applied Therapeutics For: Mar 09 Filed by: Hansard Adam -11.9%
4/21 Applied Therapeutics Announces Full Data and Scientific Presentations from the Pivotal Phase 2 ACTION-Galactosemia Trial -11.8%
6/21 Applied Therapeutics Reports First Quarter 2019 Financial Results -11.0%
12/5 Applied Therapeutics Announces Presentations Outlining the Design and Rationale for the ARISE-HF Pivotal Study of AT-001 for Treatment of Diabetic Cardiomyopathy at the 16th Annual Global Cardiovascular Clinical Trialist’s Forum (CVCT) -10.4%
3/31 Form 4 Applied Therapeutics For: Mar 27 Filed by: Alexandria Venture Investments, LLC -10.0%
3/5 Applied Therapeutics (APLT) Investor Presentation - Slideshow [Seeking Alpha] -9.3%
6/5 Form 4 Applied Therapeutics For: Jun 03 Filed by: Funtleyder Leslie D. -9.0%
8/8 Applied Therapeutics Reports AT-007 SAD Data from Healthy Volunteer Portion of Phase 1/2 ACTION-Galactosemia Study -8.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: